RA
Raffles Associates’s Lineage Cell Therapeutics LCTX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $4.89M | Sell |
5,392,088
-250,000
| -4% | -$227K | 5.1% | 7 |
|
|
2025
Q1 | $2.55M | Buy |
5,642,088
+150,000
| +3% | +$67.7K | 3.1% | 10 |
|
|
2024
Q4 | $2.76M | Buy |
5,492,088
+984,307
| +22% | +$495K | 2.97% | 12 |
|
|
2024
Q3 | $4.08M | Buy |
4,507,781
+150,000
| +3% | +$136K | 4.19% | 9 |
|
|
2024
Q2 | $4.35M | Buy |
4,357,781
+1,147,800
| +36% | +$1.14M | 4.9% | 8 |
|
|
2024
Q1 | $4.75M | Buy |
3,209,981
+1,078,360
| +51% | +$1.6M | 5.51% | 6 |
|
|
2023
Q4 | $2.32M | Buy |
2,131,621
+543,882
| +34% | +$593K | 2.94% | 10 |
|
|
2023
Q3 | $1.87M | Sell |
1,587,739
-10,000
| -0.6% | -$11.8K | 2.48% | 14 |
|
|
2023
Q2 | $2.25M | Buy |
1,597,739
+60,793
| +4% | +$85.7K | 3.03% | 10 |
|
|
2023
Q1 | $2.31M | Hold |
1,536,946
| – | – | 3.14% | 11 |
|
|
2022
Q4 | $1.8M | Sell |
1,536,946
-543,590
| -26% | -$636K | 2.1% | 13 |
|
|
2022
Q3 | $2.35M | Buy |
2,080,536
+150,000
| +8% | +$170K | 2.51% | 11 |
|
|
2022
Q2 | $3.05M | Buy |
1,930,536
+624,441
| +48% | +$987K | 3.32% | 10 |
|
|
2022
Q1 | $2.01M | Buy |
1,306,095
+762,505
| +140% | +$1.17M | 2.07% | 13 |
|
|
2021
Q4 | $1.33M | Buy |
543,590
+450,000
| +481% | +$1.1M | 1.28% | 19 |
|
|
2021
Q3 | $236K | Buy |
93,590
+50,000
| +115% | +$126K | 0.22% | 39 |
|
|
2021
Q2 | $124K | Hold |
43,590
| – | – | 0.11% | 43 |
|
|
2021
Q1 | $102K | Buy |
+43,590
| New | +$102K | 0.1% | 36 |
|
|
2018
Q3 | – | Sell |
-45,000
| Closed | -$93K | – | 52 |
|
|
2018
Q2 | $93K | Buy |
+45,000
| New | +$93K | 0.08% | 50 |
|